| PsA, n = 41 | Controls, n = 39 | p-value |
---|---|---|---|
Women | 26 (63.4) | 29 (74.4) | 0.424 |
Age, years | 54 (49–62) | 55 (46–60) | 0.458 |
Body weight, kg | 106.3 (95.8–113.6) | 104.6 (96.5–120.0) | 0.690 |
Height, m | 1.68 (1.62–1.77) | 1.66 (1.62–1.72) | 0.190 |
BMI, kg/m2 | 35.2 (34.1–38.1) | 37.7 (36.7–41.5) | 0.001 |
Waist circumference, cm | 116 (112–122) | 117 (107–126) | 0.817 |
Current smoking | 1 (2.4) | 2 (5.1) | 0.527 |
SJC 66, score | 0 (0–1) |  |  |
TJC 68, score | 4 (1–14) |  |  |
VAS patients´ global disease activity, mm | 34 (19–61) |  |  |
VAS pain, mm | 30 (19–63) |  |  |
VAS fatigue, mm | 56 (22–67) |  |  |
PsO duration, years | 32 (19–40) |  |  |
PsA symptoms duration, years | 17 (11–27) |  |  |
PsA peripheral disease | 35 (85) | Â | Â |
Axial disease | 2 (5) | Â | Â |
Combination peripheral/axial disease | 4 (10) | Â | Â |
Dactylitis ever | 21 (51) | Â | Â |
DAPSA, score | 15.3 (6.6–29.1) |  |  |
DAS28CRP, score | 2.9 (2.1–3.7) |  |  |
BSA, % | 0.8 (0–2.3) |  |  |
Leeds enthesitis index | 1 (0–4) |  |  |
NSAIDs | 26 (63) | Â | Â |
csDMARD without bDMARD | 19 (46) | Â | Â |
bDMARD | 16 (39) | Â | Â |
TNF-inhibitor | 15 (37) | Â | Â |
Methotrexate monotherapy | 13 (31.7) | Â | Â |
Apremilast | 1 (2.4) | Â | Â |
Prednisone | 3 (7.3) | Â | Â |
Ustekinumab monotherapy | 1 (2.4) | Â | Â |
IL-17- and IL-23-inhibitors | 0 | Â | Â |
CRP, mg/L | 4.0 (2.0–8.5) | 4.0 (2.0–6.0) | 0.280 |
Serum concentrations of cytokines and adipokines | |||
 TNF-α, pg/mL | 12.92 (9.99–17.20) | 11.66 (8.49–13.54) | 0.077 |
 IL-1β, pg/mL | 12.86 (6.73–19.69)c | 12.13 (5.30–14.81)d | 0.399 |
 IL-6, pg/mL | 8.72 (6.23–11.18) | 7.23 (5.54–9.47) | 0.154 |
 IL-8, pg/mL | 18.69 (13.55–23.21) | 19.28 (13.86–27.32) | 0.397 |
 IL-12/IL-23 p40, pg/mL | 602.65 (384.93–900.21)a | 544.11 (333.38–835.83)c | 0.626 |
 IL-13, pg/mL | 906.55 (679.96–1131.63)a | 885.07 (650.51–1103.93)b | 0.501 |
 IL-17, pg/mL | 2.63 (1.58–4.65)f | 0.86 (0.41–3.35)e | 0.022 |
 IL-23, ng/mL | 0.40 (0.17–0.54) | 0.54 (0.33–0.71) | 0.027 |
 IFN-γ, pg/mL | 61.98 (43.73–76.34) | 54.73 (43.83–69.95) | 0.289 |
 Resistin, ng/mL | 12.83 (10.58–15.77) | 11.82 (9.22–16.42) | 0.427 |
 Leptin, ng/mL | 26.28 (14.35–48.73) | 38.80 (20.47–59.87) | 0.059 |
 HMW adiponectin, µg/mL | 3.39 (2.13–5.12) | 4.26 (2.07–6.45) | 0.384 |
 Tot-adiponectin, µg/mL | 4.03 (3.18–6.06) | 4.16 (3.27–5.11) | 0.832 |